

Amendments to the Claims

1. **(Original)** An agent for improving a mental disorder due to cerebral dysfunction, comprising a hepatocyte growth factor.
2. **(Original)** The agent according to claim 1, wherein the mental disorder is a decline in learning function.
3. **(Original)** The agent according to claim 1, wherein the mental disorder is a decline in memory function.
4. **(Original)** The agent according to claim 1, wherein the mental disorder is dementia.
5. **(Original)** An agent for inhibiting vascular hyperpermeability, comprising a hepatocyte growth factor.
6. **(Original)** The agent according to claim 5, wherein the vascular hyperpermeability is cerebrovascular hyperpermeability.
7. **(Original)** A composition for improving a mental disorder due to cerebral dysfunction, comprising a hepatocyte growth factor and a pharmaceutically acceptable additive.
8. **(Original)** The composition according to claim 7, wherein the mental disorder is a decline in learning function.
9. **(Original)** The composition according to claim 7, wherein the mental disorder is a decline in memory function.

10. (Original) The composition according to claim 7, wherein the mental disorder is dementia.

11. (Original) A composition for inhibiting vascular hyperpermeability, comprising a hepatocyte growth factor and a pharmaceutically acceptable additive.

12. (Original) The composition according to claim 11, wherein the vascular hyperpermeability is cerebrovascular hyperpermeability.

13. (Original) A method of improving a mental disorder due to cerebral dysfunction, which comprises administering a hepatocyte growth factor to a mammal.

14. (Original) The method according to claim 13, wherein the mental disorder is a decline in learning function.

15. (Original) The method according to claim 13, wherein the mental disorder is a decline in memory function.

16. (Original) The method according to claim 13, wherein the mental disorder is dementia.

17. (Original) A method of inhibiting vascular hyperpermeability, which comprises administering a hepatocyte growth factor to a mammal.

18. (Original) The method according to claim 17, wherein the vascular hyperpermeability is cerebrovascular hyperpermeability.

19. (Currently amended) ~~Use of a hepatocyte growth factor in~~ A method for producing a pharmaceutical preparation for inhibiting a mental disorder due to cerebral dysfunction, which comprises mixing a hepatocyte growth factor with a pharmaceutically acceptable carrier.

20. (Currently amended) The use method according to claim 19, wherein the mental disorder is a decline in learning function.

21. (Currently amended) The use method according to claim 19, wherein the mental disorder is a decline in memory function.

22. (Currently amended) The use method according to claim 19, wherein the mental disorder is dementia.

23. (Currently amended) ~~Use of a hepatocyte growth factor in~~ A method for producing a pharmaceutical preparation for inhibiting vascular hyperpermeability, which comprises mixing a hepatocyte growth factor with a pharmaceutically acceptable carrier.

24. (Currently amended) The use method according to claim 23, wherein the vascular hyperpermeability is cerebrovascular hyperpermeability.